Search

Displaying results 3451 - 3460 of 4598 in total
  1. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    It was being codeveloped by Shionogi and GlaxoSmithKline.

  2. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  3. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    It is being pursued by Access Pharmaceuticals, Inc.

  4. Drug

    ChAd-triCoV/Mac

    go.drugbank.com/drugs/DB24997
    Investigational

    ChAd-triCoV/Mac is under investigation in clinical trial NCT06381739 (A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol).

  5. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion by

  6. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis.

  7. Drug

    Equilenin

    go.drugbank.com/drugs/DB03515
    Experimental

    Equilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.

  8. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  9. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.

  10. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by